Year Milestones
2017 Acquires Symbiomix Therapeutics LLC in New Jersey
Inaugurates a new plant at Sikkim
Forays into the OTC segment with Pan India launch of Softovac
Commissions a new plant at Tottori, Japan
2016 Acquires Gavis Pharma in New Jersey
Inaugurates a new plant at Visakhapatnam
Acquires the Branded Product Portfolio from Shionogi & Co. Ltd. in Japan
Bolsters the US Brands Portfolio with Methergine® Oral Tablets
2015 The Center of Excellence for Inhalation Research in Coral Springs, Florida is inaugurated
Acquires the Specialty Product Portfolio of Temmler Pharma GmbH & Co. in Germany
Acquires Medquímica Indústria Farmacêutica S.A. in Brazil
Completes the acquisition of Pharma Dynamics in South Africa
2014 Acquires Laboratorios Grin S.A. De C.V., Mexico, Specialty Ophthalmic Company and with this enters the Latin American market
Acquires Nanomi B.V.,  enters Complex Injectables Space
Inks Strategic Joint Venture Agreement with Yoshindo Inc. in Japan
2013 Inaugurates a new plant at Nagpur
Expands its branded play with exclusive US rights to Alinia® for Oral Suspensions
2012 Enters the NIFTY 50 Index
2011 Acquires I'rom Pharmaceuticals in Japan
Enters into a Joint Development Agreement with Medicis
Acquires Worldwide Rights for the Goanna® Brand
Starts commercial production  at the new Oral Solid Dosage facility at Pithampur
2010  Emerges the 5th largest Generics player in the US
2009 Acquires majority stake in Multicare Pharmaceuticals Philippines Inc.
Acquires the worldwide rights for its first NDA - AllerNaze™
Acquires the US rights for Antara®
2008 Expands its product basket in Japan-Kyowa and receives approvals for ten products from the Ministry of Health & Labour Welfare, Japan
Acquires Hormosan Pharma GmbH in Germany
Acquires a stake in Generic Health Pty Ltd., Australia
Acquires a majority stake in Pharma Dynamics, South Africa
Sets up a Biotech facility at Pune
2007 Acquires Kyowa Pharmaceutical Industry Company Ltd., a leading Generic Company in Japan
Acquires Vadodara based Rubamin Laboratories Ltd. (rechristened to Novodigm Ltd.)
Starts commercial production at the new finished dosage facility at Jammu
2006 Sets up a new facility at Jammu
Maiden Bonus shares issued in the ratio of 1:1
Maiden issue of Foreign Currency Convertible Bonds (FCCB) aggregating USD 100 million, listed on the Singapore Stock Exchange
2005 Receives the US FDA and MHRA (UK) approvals for Goa
Launches its Generics Business in the US with four products
Implements maiden Employees Stock Option Plan
Receives US FDA approval for new Lovastatin plant at Tarapur
2004 Commences its US Brands Business with the launch of Suprax®
Receives WHO approval  for state-of-the-art formulation plants at Goa and Aurangabad
2003 Lupin Pharmaceuticals Inc. USA is formed for trading, marketing and developmental activities in the US
Successfully implements SAP ERP across the Company to unify all business functions and processes
Introduces collaborative messaging and workflow solution on the Intranet
Receives US FDA approval for the Oral Cefaclor injectible plant at Mandideep
2002 Exports to the Advanced Markets cross INR 1000 million; rising trend of exports as a % of total revenue which went up 33% year-over-year
Patent filings cross 100
First five ANDAs filed
New Anti-TB facility commissioned at Aurangabad
Rablet is rated by ORG-Marg as the second best launch of FY 2002-03
2001 State-of-the-art R&D Centre, Lupin Research Park at Pune is commissioned
Commences supply of Cephalosporin bulk actives to its alliance partners in the US
Lupin Laboratories Ltd. is amalgamated with Lupin Chemicals Ltd. and rechristened to Lupin Ltd.
Becomes the only Asian pharmaceutical company to receive the US FDA approvals for its sterile Cephalosporin facility
A state-of-the-art US FDA approvable Oral Cephalosporin bulk active plant is commissioned at Mandideep
2000 Receives US FDA approval for the Cefotaxime facility at Mandideep
1999 Receives UK MCA approval for  the Injectable Cephalosporin bulk active plant at Mandideep
1997 Receives UK MCA approval for the Injectable Cephalosporin dosages plant at Mandideep
Lupin’s formulations facility at Aurangabad is upgraded
Receives US FDA approvals for three plants - Cefaclor at Mandideep, 7 ACCA at Ankleshwar and Rifampicin at Tarapur
1993 Lupin Laboratories Ltd. and Lupin Chemicals Ltd. raise money through IPOs
1992 Establishes a Fermentation Plant at Lupin Chemicals Ltd., Tarapur, Maharashtra
Commissions a Sterile Plant for Injectable Cephalosporins (bulk) at Mandideep
1991 Initiates production of Injectable Cephalosporin (bulk and dosages) at Mandideep
1989 Gets into a joint venture in Thailand and Lupin Chemicals (Thailand) Ltd. is established
Receives US FDA approvals for Ankleshwar and Mandideep plants
1988 The Lupin Human Welfare and Research Foundation (LHWRF) is founded by Dr. Desh Bandhu Gupta
1987 The Cephalexin plant at Mandideep and 7 ADCA plant at Ankleshwar go on stream
1981 Commences the production of Ethambutol
1980 Commissions first  Formulations plant and an R&D center at Aurangabad
1972 Lupin Laboratories Pvt. Ltd. is incorporated
1968 Lupin commences business